Mylan Announces Pricing for Neulasta Biosimilar
July 12, 2018 – Mylan has announced that Fulphila™ (pegfilgrastim-jmdb), its biosimilar to Amgen’s Neulasta® (pegfilgrastim), will be sold at a list price of $4,175 per syringe. The price is significantly lower than Neulasta’s list price of $6,231 per syringe.
Fulphila, which has been launched, gained U.S. FDA approval on June 4, 2018. It is the first Neulasta biosimilar to receive approval in the United States. The announced list price for the biosimilar comes in at almost $300 less per syringe than the average sale price of Neulasta.
As a biosimilar, Fulphila is not considered automatically interchangeable with Neulasta. However, like Nuelasta, it is indicated to decrease the incidence of febrile neutropenia in patients with non-myeloid malignancies who receive myelosuppressive anti-cancer drugs. Fulphila has the potential to provide these patients with a lower-cost treatment option.
Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by U.S. mail or by fax.
- Complete and submit the report Online: www.fda.gov/medwatch/report.htm
- U.S. Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
Actual drug patent expiration dates and availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval. Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval. Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.
*This is provided for information only. The reference to any medication above does not mean the medication is covered by your plan.